financetom
Business
financetom
/
Business
/
Bandhan Bank Q2 profit down 5% at Rs 920 cr
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bandhan Bank Q2 profit down 5% at Rs 920 cr
Nov 2, 2020 6:16 AM

Bandhan Bank on Monday reported 5.3 percent decline in net profit at Rs 920 crore for September quarter of the current fiscal year. The bank clocked a net profit of Rs 971.80 crore in the same period of 2019-20.

Total income grew 22 percent to Rs 2,304.90 crore in July-September 2020-21 as against Rs 1,889.30 crore in the year-ago period, Bandhan Bank said in a regulatory filing. Net interest income of the Kolkata-headquartered lender jumped 25.8 percent to Rs 1,923.1 crore during the quarter while the non-interest income grew 6.1 percent to Rs 381.8 crore.

Bandhan Bank said it has reported the highest ever quarterly profit before tax at Rs 1,233 crore during the period under review. Net Interest Margin (annualised) in the quarter fell to 8 percent against 8.2 percent in year-ago period. During the quarter, the bank took accelerated additional provision on standard advances amounting to Rs 300 crore. With this provision and the additional standard assets provision that bank is carrying in micro banking portfolio, the total additional provision in books stands at Rs 2,096 crore, it said.

The bank’s gross non-performing assets fell to 1.2 percent (Rs 874 crore) of gross advances as of September 30, 2020 as against 1.8 percent (Rs 1,064.20 crore) by the year-ago same period. Net NPAs too improved to 0.4 percent (Rs 262.50 crore) from 0.6 percent (Rs 336.90 crore).

”As the moratorium ended on 31st August 2020 coupled with robust rural performance, we have seen an all-round improvement in collection, disbursement and deposits. On deposits front, we have witnessed the best ever quarter whereas on the disbursement front, we are close to pre-COVID-19 level.”

Collections have seen a steady improvement month-on-month and is expected to reach near normal in the next 90 days. We now look forward to accelerate the business in H2FY 21,” Managing Director and CEO Chandra Shekhar Ghosh said. Total Advances grew 19.4 percent to Rs 76,614.6 crore as on September 30, 2020. Total deposits increased 34.4 percent to Rs 66,127.7 crore.

Bandhan Bank stock was trading at Rs 305.50 on BSE, up 5.62 percent from the previous close.

First Published:Nov 2, 2020 3:16 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Boeing taps debt market to raise $10 billion: sources
Boeing taps debt market to raise $10 billion: sources
Apr 29, 2024
April 29 (Reuters) - Boeing ( BA ) on Monday tapped debt markets to raise $10 billion, after the U.S. planemaker burned $3.93 billion in free cash during the first quarter following slowing production of its best-selling jet, sources familiar with the matter said. Boeing's ( BA ) credit rating hovered above junk status last week from rating agencies as...
Update: Alliance Resource Shares Rise Following Q1 Earnings Beat
Update: Alliance Resource Shares Rise Following Q1 Earnings Beat
Apr 29, 2024
12:19 PM EDT, 04/29/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph) Alliance Resource Partners ( ARLP ) shares rose 11% in recent Monday trading after the company reported Q1 earnings and revenue that topped estimates by analysts. Q1 earnings fell to $1.21 per diluted limited partner unit from $1.45 a year earlier, the...
Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday?
Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday?
Apr 29, 2024
On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc ( DCPH ) for $25.60 per share in cash, for a total equity value of $2.4 billion.  Deciphera brings specialized research and development capabilities in kinase drug discovery, well-established commercial and sales platforms in the United States and Europe, and global clinical development capabilities.  In addition to QINLOCK – Deciphera’s switch-control inhibitor...
Deciphera Agrees to $2.4 Billion Buyout Offer From Japan's ONO Pharmaceutical
Deciphera Agrees to $2.4 Billion Buyout Offer From Japan's ONO Pharmaceutical
Apr 29, 2024
12:16 PM EDT, 04/29/2024 (MT Newswires) -- Deciphera Pharmaceuticals ( DCPH ) on Monday agreed to be acquired by Japan-based ONO Pharmaceutical through a tender offer in a deal worth roughly $2.4 billion. Under the terms, investors of the US biopharmaceutical company will receive $25.60 per share in cash, representing a premium of about 75% to its closing price on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved